AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (924.2 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese | Open Access

Pharmacokinetics and residual elimination pattern of enrofloxacin and its metabolite ciprofloxacin in Babylonia areolate

Dong DENG1, Yongsen WEN1, Xiaokun LIU1, Wengang LYU1,2,3( ), Jinglei CHEN3, Jingbu CHEN3
Fisheries College, Guangdong Ocean University, Zhanjiang 524088, China
Invertebrate Science and Technology Innovation Center, Zhanjiang 524088, China
Hainan Kangguan Biotechnology Co., Ltd., Wenchang 571300, China
Show Author Information

Abstract

In recent years, frequent occurrence of enrofloxacin residues in breeding snail (Babylonia areolate) has been a problem. To reveal the pharmacokinetic characteristics of enrofloxacin and its metabolites in B. areolate, and to design a rational dosing method and the rest period, we fed B. areolate with 20 mg·kg−1 of enrofloxacin mixture at water temperature of (24.5 ± 2.5) ° C, and then sampled at 0.17th, 0.25th, 0.5th, 1st, 2nd, 4th, 12th, 24th, 48th, 72nd, 120th, 168th, 240th and 360th hour after the dosing. Shimadzu 8050 LC-MS/MS was used to determine the drug concentration in the tissues in each period. The results show that the drug-time data applied to the non-atrial models in Gastropod muscle, proboscis (Including esophageal glands) and liver: the Cmax of enrofloxacin was 7.82, 10.5 and 31.47 mg·kg−1, respectively; the Cmax of ciprofloxacin (Metabolite) was 0.72, 0.89 and 1.21 mg·kg−1, respectively; the enrofloxacin tmax was 1, 4 and 4 h, respectively; the ciprofloxacin tmax was 4, 12 and 4 h, respectively; the enrofloxacin t1/2z was 38.22, 52.44 and 62.40 h, respectively; the ciprofloxacin t1/2z was 66.23, 33.11 and 27.06 h, respectively; the theoretical drug rest period was 16.94, 16.79 and 17.99 d, respectively. The results indicate that for all tissues, 20 mg·kg−1 of enrofloxacin mixture with the Cmax/MIC over 10 is suitable for the treatment of B. areolate disease caused by Vibrio harveyi (MIC, 0.45 mg·L−1). It is recommended that the drug rest period should not be less than 440.76 ℃·d and the dosing should be once every 2 d, a total of 3 times.

CLC number: S 948 Document code: A Article ID: 2095-0780-(2024)06-0176-11

References

【1】
【1】
 
 
South China Fisheries Science
Pages 176-186

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
DENG D, WEN Y, LIU X, et al. Pharmacokinetics and residual elimination pattern of enrofloxacin and its metabolite ciprofloxacin in Babylonia areolate. South China Fisheries Science, 2024, 20(6): 176-186. https://doi.org/10.12131/20240152

1

Views

0

Downloads

0

Crossref

0

Scopus

0

CSCD

Received: 04 July 2024
Revised: 29 August 2024
Published: 05 December 2024
© Editorial Office of South China Fisheries Science.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).